Protox Therapeutics Inc. Files IND For The Treatment Of Prostate Cancer
Protox Therapeutics Inc. announced today that
it has submitted an investigational new drug (IND) application to the U.S.
Food and Drug Administration (FDA) for the Company's lead product, PRX302.
Protox plans to initiate Phase 1 clinical trials of PRX302, for the treatment
of recurrent localized prostate cancer, early next year upon approval of the
IND by the FDA.